Absolute Bargaining Power Enables Capture of Full Joint Surplus

A firm is the sole provider of a specialized component essential for manufacturing a popular electronic device. The firm offers this component to a device manufacturer under a strict 'take-it-or-leave-it' contract, meaning the manufacturer can only accept the proposed price and terms or reject the deal entirely, with no opportunity for counter-offers. Which statement best analyzes the source of the component supplier's bargaining power in this specific negotiation?

In a negotiation where one party makes a 'take-it-or-leave-it' offer, the proposer's complete bargaining power stems primarily from their ability to set a price that is only marginally better than the other party's next best alternative.

Source of Bargaining Power

The Power of Non-Negotiable Offers

In a negotiation scenario where one party makes a single, non-negotiable proposal, match each element of the interaction with its direct effect on bargaining power.

Evaluating Bargaining Structures

In a negotiation where one party can only make a single, non-negotiable proposal that the other party must either accept or reject, the proposer's complete bargaining power originates from the established ______ of the interaction.

In a negotiation, one party is designated as the sole proposer of a deal, and the other party can only accept or reject this single proposal without any opportunity for counter-offers. Arrange the following statements into the correct logical order to explain how this specific rule structure results in the proposer holding all the bargaining power.

Evaluating Claims of Absolute Bargaining Power

A pharmaceutical company holds the exclusive patent for a life-saving drug and offers it to a national healthcare system under a strict 'take-it-or-leave-it' contract. The healthcare system can only accept the company's proposed price or reject the deal entirely. Subsequently, a new government regulation is enacted that allows the healthcare system to make one, and only one, counter-offer, which the company can then either accept or reject. How does this modification to the negotiation process affect the pharmaceutical company's initial bargaining power?